Are You Ready for the Fourth Industrial Revolution? When Biotechnology Transforms Healthcare
DATE : 25 April, 2019 (Thursday)
TIME : 2:00-3:00pm
VENUE : Seminar Room 2 (LG-S2), G/F., Laboratory Block, Li Ka Shing Faculty of Medicine, 21 Sassoon Road, Hong Kong
SPEAKERS : Dr Min-Han Tan, Founding CEO & Medical Director of Lucence Diagnostics
Revolutions in biology and computer science are changing healthcare worldwide. Here in Asia, home to 60% of the world's population, we are witnessing the beginning of a transformation unprecedented in size and scale. Healthcare is expected to be a cornerstone of the Fourth Industrial Revolution, which is characterized by a range of new technologies that are fusing the physical, digital and biological worlds, and would open up new opportunities but would also pose new challenges to humanity and businesses.
This talk will reflect the founder's perspective of Lucence Diagnostics, a genomic medicine technology company. The company now operates in Singapore, San Francisco, Hong Kong and Suzhou, marrying new sequencing technologies and AI to enable earlier and more accurate cancer diagnosis with lower costs. The speaker would share the challenges encountered during growth as well as insights and potential opportunities for growing deep healthcare technology in the fastest growing economic region in the world will also be shared.
About the Speaker :
Dr Min-Han Tan is a trained medical oncologist and clinical cancer geneticist, In 2011, he joined A*STAR in Singapore to lead the Laboratory of Systems Medicine. He subsequently founded Lucence in 2016 to commercialize the cancer diagnostic technology his lab developed at A*STAR.
Dr Tan has published over 100 original research publications in journals and filed more than 12 patents. He is recognized internationally for his landmark discovery of circulating tumor-endothelial cell clusters in the blood of cancer patients, which overturned a 50-year scientific dogma. As a clinical cancer geneticist, Dr Tan reported the international diagnostic criteria and lifetime cancer risks for Cowden syndrome, a hereditary breast cancer syndrome.
For his track record of disruptive innovation in research and clinical medicine, Dr Tan has been recognized with awards from the American Society of Clinical Oncology, the European Society of Medical Oncology and the Association of Southeast Asian Nations. He was elected Fellow of the Royal College of Physicians Edinburgh in 2015 and received the A*STAR Outstanding Scientist-Entrepreneur Award in 2018.
For HKU Staff and Students : https://goo.gl/ve611L
For Others : https://goo.gl/aviCxa